AARD vs SLB · $284.4M cap vs P/E 12, rev $8.97B
Aardvark Therapeutics, Inc. Common Stock (AARD) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported SLB revenue for 2026-06-30 was $8.97B. Net income was $786.0M. Revenue was up 2.9% from 2026-03-31 to 2026-06-30. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
AARD currently screens at market cap $284.4M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the AARD and SLB stock pages for the full models.
Not investment advice.